Loading
A phase 3 trial testing HRS-8080 in HR-positive / HER2-negative breast cancer, now recruiting.
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer is a phase 3 interventional study registered as NCT07349069, led by Shandong Suncadia Medicine, and recruiting on the registry. Official title: A Randomised, Open-Label, Phase III Trial to Compare HRS-8080 Versus Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer Who Have Received at Least 2 Years of Standard Adjuvant Endocrine Therapy. Planned enrolment is 5500 participants (estimated). The study started in 2026-03-04 and primary completion is expected in 2030-12. No results have been posted on ClinicalTrials.gov.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares High-risk early HR-positive breast cancer, HR-positive / HER2-negative breast cancer.